Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors

Summary

This is a phase 1 study to evaluate the safety of intralesional talimogene laherparepvec administration in pediatric subjects with advanced non-CNS tumors that are amenable to direct injection

Timeline

Start

2017-08-16

Primary completion

2022-01-17

Completion

2022-11-29

Publications

• Background Moreno L, Teira P, Croop JM, Gerber NU, Andre N, Aerts I, Gros Subias L, De Wilde B, Bautista F, Turpin B, Kunduri S, Hamidi A, Lawrence T, Streby KA. A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors. Front Pediatr. 2023 May 24;11:1183295. doi: 10.3389/fped.2023.1183295. eCollection 2023.

Drugs

Indications